Want to see RLMD full AI Analyst Report?
RLMD Stock Chart & Stats
$4.59
-$0.02(-0.38%)
At close: 4:00 PM EDT
$4.59
-$0.02(-0.38%)
Day’s Range― - ―
52-Week Range$1.98 - $8.00
Previous CloseN/A
Volume1.65M
Average Volume (3M)1.38M
Market Cap
$358.41M
Enterprise Value$559.91M
Total Cash (Recent Filing)$217.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 05, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding106,669,846
10 Day Avg. Volume1,398,697
30 Day Avg. Volume1,377,516
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-4.16
Enterprise Value/Market Cap1.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.04
Forecast
1Y Price Target
$12.00Price Target Upside161.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayThe strengthened cash position gives Relmada substantial funding visibility for planned clinical development and reduces near-term financing pressure. A runway extending through 2029 supports execution of Phase III activities and allows management to pursue milestones without immediate dependence on external capital.
NDV-01 Clinical EvidenceStrong 12-month Phase II efficacy and favorable safety provide a meaningful clinical foundation for advancing NDV-01. Durable responses can support regulatory discussions, improve the program’s competitive position, and increase the potential value of successful late-stage development.
Regulatory Development PathFDA alignment and defined registration pathways reduce uncertainty around the intended development strategy for NDV-01. Combined with planned IND filing and prepared clinical sites, this creates a clearer route from current development work toward registrational testing and potential commercialization.
Bears Say
Pre-Commercial LossesRelmada remains dependent on development progress rather than product revenue, while substantial operating losses and negative cash flow continue. Until a program reaches commercialization, the company must fund research and clinical activity from existing resources or future financing, creating ongoing financial execution risk.
CMC Execution DelayManufacturing scale-up and stability work are still required before the NDV-01 IND can be filed, making CMC execution a central near-term dependency. Further delays could postpone Phase III initiation, extend development spending, and defer the regulatory milestones needed to validate the program.
Rising Development BurnAccelerating R&D and manufacturing investment reflects a more intensive development phase but also increases the rate at which Relmada consumes cash. If spending remains elevated before revenue begins, the company’s runway could shorten and future financing or dilution risk could become more important.
Relmada Therapeutics News
RLMD FAQ
What was Relmada Therapeutics’s price range in the past 12 months?
Relmada Therapeutics lowest stock price was $1.98 and its highest was $8.00 in the past 12 months.
What is Relmada Therapeutics’s market cap?
Relmada Therapeutics’s market cap is $358.41M.
When is Relmada Therapeutics’s upcoming earnings report date?
Relmada Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were Relmada Therapeutics’s earnings last quarter?
Relmada Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.09.
Is Relmada Therapeutics overvalued?
According to Wall Street analysts Relmada Therapeutics’s price is currently Undervalued.
Does Relmada Therapeutics pay dividends?
Relmada Therapeutics does not currently pay dividends.
What is Relmada Therapeutics’s EPS estimate?
Relmada Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Relmada Therapeutics have?
Relmada Therapeutics has 106,669,846 shares outstanding.
What happened to Relmada Therapeutics’s price movement after its last earnings report?
Relmada Therapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -8.007%.
Which hedge fund is a major shareholder of Relmada Therapeutics?
Currently, no hedge funds are holding shares in RLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (161.44% Upside)
$12.00 (161.44% Upside)
Blogger Sentiment
Bullish
RLMD Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.30%
12-Months-Change
Fundamentals
Return on Equity
-47.52%
Trailing 12-Months
Asset Growth
937.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Relmada Therapeutics
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and execution-focused tone: Relmada reported a materially strengthened balance sheet (cash +134% YoY) with a cash runway into 2029, compelling 12-month Phase II efficacy and favorable safety for NDV-01, clear FDA-aligned registration pathways, an experienced new CBO, and engaged clinical sites. Key near-term risks center on manufacturing/CMC execution (GMP batch production and stability data), which shifted IND timing toward year-end 2026 and has increased R&D spend and operating cash use. On balance the company appears well-capitalized and positioned to advance registrational programs, but outcomes hinge on resolving manufacturing scale-up and timing.View all RLMD earnings summariesRLMD Stock 12 Month Forecast
Average Price Target
$12.00
▲(161.44% Upside)
Technical Analysis
Ownership Overview
3.19% Insiders
3.68% Mutual Funds
0.07% Other Institutional Investors
81.69% Public Companies and
Individual Investors